Skip to main content
ANTEROGEN CO., LTD. logo

ANTEROGEN CO., LTD. — Investor Relations & Filings

Ticker · 065660 ISIN · KR7065660003 KO Manufacturing
Open in API
Filings indexed 267 across all filing types
Latest filing 2022-05-13 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 065660

About ANTEROGEN CO., LTD.

http://anterogen.com

ANTEROGEN CO., LTD. is a bio-venture company engaged in the research, development, and commercialization of cell therapy products and orphan drugs. The company specializes in utilizing adult stem cells, particularly adipose-derived mesenchymal stem cells, to create innovative treatments. Its key commercialized products include Cupistem®, an autologous stem cell therapy for Crohn's fistula, and Queencell®. Anterogen's research pipeline extends to applications for musculoskeletal diseases, spinal injuries, and cardiovascular conditions. The company also offers stem cell banking services.

Recent filings

Filing Released Lang Actions
[기재정정]분기보고서 (2022.03)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for the company 'Anterogen' (주식회사 안트로젠) covering the period from January 1, 2022, to March 31, 2022. It contains detailed financial information, business operations, management discussion, and capital structure, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2022
2022-05-13 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the shareholding status and changes in ownership for Antrogen Co., Ltd. by its major shareholder and special related parties. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2022-03-31 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official report of the results of an Annual General Meeting (AGM) for the company 'Antrogen'. It details the approval of financial statements, dividend resolutions, election of directors and auditors, and other agenda items voted upon during the meeting held on 2022-03-16. This aligns perfectly with the definition of a Declaration of Voting Results (DVA).
2022-03-16 Korean
대표이사변경
Board/Management Information Classification · 100% confidence The document is a formal announcement regarding a change in the company's representative director (CEO). It explicitly lists the 'before' and 'after' representatives, the reason for the change, and the date of the board resolution. This falls directly under the definition of Board/Management Information (MANG).
2022-03-16 Korean
전환가액의조정(제5회차)
Capital/Financing Update Classification · 100% confidence The document is an official regulatory filing from Antrogen regarding the adjustment of the conversion price for its 5th series convertible bonds. It details the change in conversion price, the number of convertible shares, and the methodology used for the adjustment based on market price fluctuations. This type of disclosure regarding capital structure and debt-to-equity conversion terms falls under 'Capital/Financing Update'.
2022-03-08 Korean
전환사채(해외전환사채포함)발행후만기전사채취득(제5회차)
Capital/Financing Update Classification · 100% confidence The document is a regulatory filing from the Korean Exchange (KRX) regarding the acquisition of convertible bonds before maturity (early redemption). It details the specific bond series, acquisition amount, reason for acquisition (put option exercise), and future treatment (cancellation). This falls under capital structure changes and financing updates, specifically related to debt instruments.
2022-03-08 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.